News & Media

News Releases

March 30, 2023

Combined Therapeutics to Present its Next-Generation mRNA-Based Vaccine Platform at the World Vaccine Congress 2023

BOSTON, March 30, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx) today announced its participation in the upcoming World Vaccine Congress 2023, taking place in Washington, D.C., April 4-6, where it will present its cutting-edge mRNA-based vaccine technology MOPCTx in a poster presentation and oral…

March 13, 2023

Combined Therapeutics Granted Patent for its mRNA Vaccine Platform by USPTO

BOSTONMarch 13, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx) today announced its intellectual property position reinforcement in mRNA vaccine technology with the issue of U.S. Patent 11,596,685 by the United States Patent and Trademark Office (USPTO) on March 7,…

March 8, 2023

Combined Therapeutics Expands Board of Directors with Appointments of Biopharma Industry Veterans Paul Wotton, Robert Ruffolo and Kevin F. McLaughlin

BOSTONMarch 8, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA therapeutics with a novel modified-mRNA platform to prevent and treat infectious diseases and cancer, today announced the appointment of three highly accomplished biopharma executives to its board of directors:  Paul Wotton, Ph.D.;